{
      "Rank": 316,
      "Acronym": [
            "BOOSTB4"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "15 participants.\n\nAdministration of four postnatal doses of BOOST cells with the first dose as soon as possible after birth and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.",
            "15 participants.\n\nAdministration of one prenatal dose of BOOST cells followed by three postnatal doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.",
            "1-30 participants.\n\nSubjects eligible for the trial but not willing/able to participate in any of the experimental arms.",
            "30-150 participants.\n\nMatched historical controls. Subjects will be identified in historical registries and data will be retrieved from national OI registers and the OI Variant Database (Dalgleish 2018)."
      ],
      "ArmGroupInterventionName": [
            "Biological: BOOST cells",
            "Biological: BOOST cells"
      ],
      "ArmGroupLabel": [
            "Postnatal",
            "Prenatal",
            "Prospective control (untreated)",
            "Historic control"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental",
            "No Intervention",
            "No Intervention"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03706482"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "An exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a combination of historical and untreated prospective controls."
      ],
      "BriefTitle": [
            "Boost Brittle Bones Before Birth"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER",
            "OTHER"
      ],
      "CollaboratorName": [
            "Karolinska University Hospital",
            "Great Ormond Street Hospital for Children NHS Foundation Trust",
            "University College, London",
            "Universit\u00e4tsklinikum K\u00f6ln",
            "UMC Utrecht",
            "Leiden University Medical Center",
            "Lund University"
      ],
      "CompletionDate": [
            "December 30, 2031"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "Osteogenesis Imperfecta"
      ],
      "ConditionAncestorId": [
            "D000010009",
            "D000001848",
            "D000001847",
            "D000009140",
            "D000030342",
            "D000003095",
            "D000003240"
      ],
      "ConditionAncestorTerm": [
            "Osteochondrodysplasias",
            "Bone Diseases, Developmental",
            "Bone Diseases",
            "Musculoskeletal Diseases",
            "Genetic Diseases, Inborn",
            "Collagen Diseases",
            "Connective Tissue Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC05",
            "BC16",
            "BC17",
            "All",
            "BC18",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Musculoskeletal Diseases",
            "Diseases and Abnormalities at or Before Birth",
            "Skin and Connective Tissue Diseases",
            "All Conditions",
            "Nutritional and Metabolic Diseases",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Osteogenesis Imperfecta",
            "Osteogenesis Imperfecta"
      ],
      "ConditionBrowseLeafId": [
            "M12088",
            "M12084",
            "M11195",
            "M4278",
            "M4279",
            "M11249",
            "M22839",
            "M14197",
            "M5475",
            "M5616",
            "T4306",
            "T4309",
            "T3909"
      ],
      "ConditionBrowseLeafName": [
            "Osteogenesis Imperfecta",
            "Osteochondrodysplasias",
            "Mucopolysaccharidosis IV",
            "Bone Diseases",
            "Bone Diseases, Developmental",
            "Musculoskeletal Diseases",
            "Genetic Diseases, Inborn",
            "Rheumatic Diseases",
            "Collagen Diseases",
            "Connective Tissue Diseases",
            "Osteogenesis Imperfecta",
            "Osteogenesis Imperfecta Type III",
            "Mucopolysaccharidosis Type IV"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000010013"
      ],
      "ConditionMeshTerm": [
            "Osteogenesis Imperfecta"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Non-Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria Postnatal Group:\n\nParent's/legal guardian's signed informed-consent form\nClinical diagnosis of OI type III or IV AND\nMolecular diagnosis of OI (Glycine substitution in the collagen triple-helix encoding region of either the COL1A1 or COL1A2 gene)\nAge less than 18 months (calculated from gestational week 40+0, i.e. the corrected age)\nParent/legal guardian over 18 years of age\n\nInclusion Criteria Prenatal Group:\n\nWoman has signed the informed-consent form\nOnly women where termination of the pregnancy is no longer possible or where the women are committed to continue the pregnancy may be included in the trial\nSuspicion of OI type III or IV in the fetus on ultrasound findings AND\nMolecular diagnosis of OI in the fetus (Glycine substitution in the collagen triple-helix encoding region of either the COL1A1 or COL1A2 gene)\nGestation age between 16+0 and 35+6 weeks+days\nPregnant woman over 18 years of age\n\nInclusion Criteria Historical Control Group:\n\nParent's/legal guardian's signed informed-consent form\nClinical and molecular diagnosis of OI (Glycine substitution in the collagen triple-helix encoding region of either the COL1A1 or COL1A2 gene)\nData on fractures and growth is available\nParent/legal guardian over 18 years of age\n\nInclusion Criteria Prospective Untreated Control Group:\n\nPostnatal inclusion: The inclusion criteria for the postnatal group apply.\nPrenatal inclusion: The inclusion criteria for the prenatal group apply, except inclusion criteria 2.\n\nExclusion Criteria Postnatal Group:\n\nExistence of other known disorder that might interfere with the treatment, such as, but not limited to organ dysfunction (for example liver or renal failure or bronchopulmonary dysplasia), congenital heart defect, hypoxic encephalopathy l-lll, severe neurological problems, immune deficiencies, muscle diseases, severe malformations or syndromes diagnosed by clinical examination.\nAny contraindication for invasive procedures such as a moderate/severe bleeding tendency\nKnown risk factors for clotting, such as, but not limited to previous blood clot, family history of clots, clotting disorder (inherited or acquired), heart failure, inflammatory disorders (for example lupus, rheumatoid arthritis, inflammatory bowel disease)\nPositive Donor Specific Antibody-test\nKnown allergy/hypersensitivity to Fungizone and/or Gensumycin\nAbnormal karyotype or other confirmed genetic syndromes\nOncologic disease (previous or current malignancy)\nInability to comply with the trial protocol and follow-up schedule\nInability to understand the information and to provide informed consent\n\nExclusion Criteria Prenatal Group:\n\nMultiple pregnancy\nCo-existence of other disorder that might interfere with the treatment, as judged by the Investigator or the patient's obstetrician\nAbnormal fetal karyotype or other confirmed genetic syndrome\nAny contraindication for invasive procedures such as a bleeding tendency or contagious infections, such as, but not limited to HIV, Syphilis, Hepatitis B, Hepatitis C or other known infectious diseases that can harm the fetus\nKnown risk factors for clotting, such as, but not limited to previous blood clot, family history of clots, clotting disorder (inherited or acquired), heart failure, inflammatory disorders (for example lupus, rheumatoid arthritis, inflammatory bowel disease)\nPositive Donor Specific Antibody-test\nKnown allergy/hypersensitivity to Fungizone and/or Gensumycin\nOncologic disease in woman or fetus (previous or current malignancy)\nUnwilling to or cannot undergo delivery by elective Caesarean section\nInability to comply with the trial protocol and follow-up schedule\nInability to understand the information and to provide informed consent\n\nExclusion Criteria Historical Control Group:\n\nExistence of other disorder that might interfere with the trial\nAbnormal karyotype\n\nExclusion Criteria Prospective Untreated Control Group:\n\nPostnatal inclusion: The exclusion criteria, except exclusion criterium 2, 3, 4 and 5 for the postnatal group apply.\nPrenatal inclusion: The exclusion criteria, except exclusion criterium 1, 4, 5, 6 and 7 for the prenatal group apply."
      ],
      "EnrollmentCount": [
            "18"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Postnatal",
            "Prenatal"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Hemat",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Hematinics",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M10262"
      ],
      "InterventionBrowseLeafName": [
            "Liver Extracts"
      ],
      "InterventionBrowseLeafRelevance": [
            "low"
      ],
      "InterventionDescription": [
            "Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "BOOST cells"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "October 3, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "September 30, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Karolinska Institutet"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Stockholm"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Sweden"
      ],
      "LocationFacility": [
            "Karolinska University Hospital"
      ],
      "LocationState": [],
      "LocationStatus": [],
      "LocationZip": [
            "171 76"
      ],
      "MaximumAge": [
            "18 Months"
      ],
      "MinimumAge": [],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "An Exploratory, Open Label, Multiple Dose, Multicentre Phase I/II Trial Evaluating Safety and Efficacy of Postnatal or Prenatal and Postnatal Intravenous Administration of Allogeneic Expanded Fetal Mesenchymal Stem Cells for the Treatment of Severe Osteogenesis Imperfecta Compared With a Combination of Historical and Untreated Prospective Controls"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Karolinska Institutet"
      ],
      "OrgStudyId": [
            "KIBB01"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [
            "Quality of life assessed using the Infant Toddler Quality of Life Questionnaire\u2122 (ITQOL).",
            "Donor cell engraftment.",
            "Paracrine effects will be analysed from plasma isolated from peripheral blood.",
            "Non-invasive prenatal diagnosis will be studied during the trial."
      ],
      "OtherOutcomeMeasure": [
            "Impact on the subjects Quality of Life: Infant Toddler Quality of Life Questionnaire\u2122 (ITQOL)",
            "Incidence of donor cells engrafted into patient tissue samples assessed by histology.",
            "Analysis of an array of cytokines and micro vesicles to evaluate paracrine effects.",
            "Assess the potential of non-invasive methods of prenatal diagnosis for OI by genetic analysis of parent DNA."
      ],
      "OtherOutcomeTimeFrame": [
            "From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose).",
            "From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose).",
            "From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose).",
            "From baseline to birth for prenatal group."
      ],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Karolinska University Hospital"
      ],
      "OverallOfficialName": [
            "Eva \u00c5str\u00f6m, MD PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Active, not recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 30, 2031"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "The primary endpoint is safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs), with specific focus on the following:\n\nVital signs in conjunction with the MSC administration\nTransfusion reactions (administration toxicity, allergy, embolism)\n\nImmune reaction with or without symptoms of inflammation, potentially resulting in rejection of the cells or development of donor-specific antibodies:\n\nAllergy or Hypersensitivity responses to antibiotics or antimycotics\nDevelopment of Fetal Bovine Serum-specific antibodies\nHypersensitivity responses to Human Serum Albumin\nHypersensitivity to impurities in the IMP\nPrenatal complications (miscarriage/intrauterine fetal death, premature birth, infection in utero or persistent [>1 min] fetal bradycardia) in the prenatal group\nAdverse effects of feto-maternal transmission of donor cells in the prenatal group\nTumourigenicity\nMortality/morbidity"
      ],
      "PrimaryOutcomeMeasure": [
            "Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events."
      ],
      "PrimaryOutcomeTimeFrame": [
            "From baseline to the long-time follow-up (10 years after the first dose)."
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Karolinska Institutet"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Cecilia G\u00f6therstr\u00f6m"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Sponsor's representative"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Number of fractures.",
            "Time (days) to first fracture after each stem cell administration.",
            "Numbers of fractures at birth.",
            "Change in bone-marrow density (g/cm2).",
            "Growth (cm) as assessed by clinician.",
            "Growth (kg) as assessed by clinician.",
            "Change in clinical status of OI based on parameters defined under efficacy assessments described in protocol, as assessed by OI clinician.",
            "Assessment of biochemical bone turnover."
      ],
      "SecondaryOutcomeMeasure": [
            "Number of fractures.",
            "Time (days) to first fracture after each stem cell administration.",
            "Numbers of fractures at birth.",
            "Change in bone-marrow density (g/cm2).",
            "Growth (cm).",
            "Growth (kg).",
            "Change in clinical status of OI.",
            "Assessment of biochemical bone turnover by analysis of the markers P-Calcium, P-Phosphate, P-Albumin, S-ALP, fP-PTH, S-25-OH Vitamin D, Bone specific S-ALP, S-CTx, S-Osteocalcin and U-DPD/Krea and U-NTx/Krea in blood and urine samples."
      ],
      "SecondaryOutcomeTimeFrame": [
            "From baseline to the primary follow-up (6 and 12 months after the last dose) and therafter assessed annually to the end of the long-time follow-up (10 years after the first dose).",
            "From each dose of stem cells to the time point of the first fracture. Assessed up to 10 years after the first stem cell dose.",
            "Evaluated at birth.",
            "From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose).",
            "From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose).",
            "From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose).",
            "From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose).",
            "From baseline to the primary follow-up (6 and 12 months after the last dose) and thereafter assessed annually to the end of the long-time follow-up (10 years after the first dose)."
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "August 12, 2019"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "September 2022"
      ],
      "StdAge": [
            "Child"
      ],
      "StudyFirstPostDate": [
            "October 16, 2018"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "October 5, 2018"
      ],
      "StudyFirstSubmitQCDate": [
            "October 10, 2018"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}